Type 2 diabetes clinical trial – COMBINE

  26 October 2022  Barwon Health   |   Third party content – view disclaimer

Barwon Health is currently looking for participants for a clinical trial in type 2 diabetes called COMBINE 1.

COMBINE is a global programme of clinical studies to investigate how well a new combination therapy taken once weekly, IcoSema (insulin icodec and semaglutide), controls blood sugar levels in people with diabetes. The investigational product once weekly IcoSema will be compared with its individual components taken once weekly and with insulins taken daily.

As part of the programme, this study is comparing the effect and safety of once weekly IcoSema, with that of once weekly insulin icodec (also an investigational product), over a period of 14 months. Adults with type 2 diabetes may qualify for this study if they have been treated with a once or twice-daily basal insulin.

Please note: current GLP-1 therapy excludes participation. There will be a $200 payment to GPs for every participant screened into the study.

For more information please call Study Coordinator, Fahriya Zandari on (03) 4215 2877 or email Fahriya.Zandari@barwonhealth.org.au

Disclaimer: This article was provided by Barwon Health. While every effort has been made to ensure the information is accurate, North Western Melbourne Primary Health Network does not warrant or represent the accuracy, currency and completeness of any information or material included within.